- Home
- TS vs GMAB Comparison
TS vs GMAB Comparison
Compare TS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TS
- GMAB
- Stock Information
- Founded
- TS 2001
- GMAB 1999
- Country
- TS Luxembourg
- GMAB Denmark
- Employees
- TS N/A
- GMAB N/A
- Industry
- TS Steel/Iron Ore
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TS Industrials
- GMAB Health Care
- Exchange
- TS Nasdaq
- GMAB Nasdaq
- Market Cap
- TS 18.8B
- GMAB 15.4B
- IPO Year
- TS N/A
- GMAB N/A
- Fundamental
- Price
- TS $35.83
- GMAB $27.82
- Analyst Decision
- TS Buy
- GMAB Buy
- Analyst Count
- TS 5
- GMAB 6
- Target Price
- TS $43.20
- GMAB $37.60
- AVG Volume (30 Days)
- TS 1.7M
- GMAB 1.4M
- Earning Date
- TS 11-05-2025
- GMAB 11-05-2025
- Dividend Yield
- TS 4.63%
- GMAB N/A
- EPS Growth
- TS N/A
- GMAB 77.72
- EPS
- TS 1.84
- GMAB 21.62
- Revenue
- TS $11,768,597,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- TS N/A
- GMAB $22.68
- Revenue Next Year
- TS N/A
- GMAB $15.85
- P/E Ratio
- TS $9.39
- GMAB $1.29
- Revenue Growth
- TS N/A
- GMAB 32.97
- 52 Week Low
- TS $28.07
- GMAB $17.24
- 52 Week High
- TS $40.87
- GMAB $28.75
- Technical
- Relative Strength Index (RSI)
- TS 50.09
- GMAB 70.96
- Support Level
- TS $34.94
- GMAB $27.58
- Resistance Level
- TS $35.72
- GMAB $28.75
- Average True Range (ATR)
- TS 0.67
- GMAB 0.39
- MACD
- TS 0.04
- GMAB 0.19
- Stochastic Oscillator
- TS 61.03
- GMAB 79.28
About TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.